TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9280206
Drug: Dietary salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary salt restriction with a low-salt diet (20 mmol sodium chloride per day) and a supplement of 20 tablets of slow sodium (10 mmol NaCl per tablet) for 7 days
Study: 8301803
Drug: TPN during
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPN during chemotherapy
Study: 23489113
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of terlipressin (4 mg/24 h)
Study: 23489113
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of terlipressin (2 mg) followed by intermittent injections (1 mg/6 h)
Study: 15046380
Drug: Meloxicam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (7.5 mg)
Study: 15046380
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three drugs (nimesulide, meloxicam, rofecoxib)
Study: 9836480
Drug: Cisplatin (single-agent,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (single-agent, higher dose)
Study: 8157946
Drug: Captopril (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (average dose 72 mg/day for 24 weeks)
Study: 15123028
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam 0.2 mg/kg
Study: 28893496
Drug: Moist hot
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moist hot pack (MHP) for 15 minutes during therapy
Study: 28893496
Drug: Therapeutic whirlpool
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic whirlpool bath (WB) for 15 minutes during therapy
Study: 25106447
Drug: Co-careldopa treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-careldopa treatment in addition to routine NHS occupational and physical therapy
Study: 25106447
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in addition to routine NHS occupational and physical therapy
Study: 17595175
Drug: Immediate incentives
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate incentives ($5 weekly)
Study: 27454263
Drug: Ibuprofen 50
Normalized name: ibuprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 50 mg
Study: 3547351
Drug: Ibuprofen 100
Normalized name: ibuprofen 100 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 100 mg
Study: 9602959
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication (Acetaminophen 500 mg)
Study: 8027413
Drug: Bupropion (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (225 to 450 mg/day)
Study: 8027413
Drug: Trazodone (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (150 to 400 mg/day)
Study: 4851085
Drug: MOPP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP treatment plus bleomycin
Study: 4851085
Drug: MOPP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP treatment
Study: 4851085
Drug: MOPP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP treatment (maintained group for 24 months)
Study: 28177725
Drug: Phosphatidic acid
Normalized name: LYSOPHOSPHATIDIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidic acid (PA) supplementation (750 mg)
Study: 9535996
Drug: LAAM 20
Normalized name: LAAM
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM 20 mg/70 kg i.v.
Study: 9535996
Drug: LAAM 40
Normalized name: LAAM
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM 40 mg/70 kg i.v.
Study: 9535996
Drug: LAAM 20
Normalized name: LAAM
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM 20 mg/70 kg p.o.
Study: 9535996
Drug: LAAM 40
Normalized name: LAAM
DrugBank: Levacetylmethadol (DB01227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAAM 40 mg/70 kg p.o.
Study: 8070500
Drug: U-62066E with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-62066E with high dose naloxone
Study: 8070500
Drug: U-62066E with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: U-62066E with low dose naloxone
Study: 2653893
Drug: gemeprost 1
Normalized name: Gemeprost 1 mg vaginal pessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemeprost 1 mg vaginal pessaries at 3 hours intervals up to a maximum of 5 mg
Study: 2653893
Drug: PGF2 alpha
Normalized name: Prostaglandin PGF2 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGF2 alpha 40 mg intra-amniotic dose
Study: 1091343
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (sustained-release capsule and regular tablet)
Study: 28099485
Drug: Unadjuvanted H5N1
Normalized name: influenza, H5N1-1203
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unadjuvanted H5N1 vaccine
Study: 29911772
Drug: 5% minoxidil
Normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% minoxidil milky lotion
Study: 20852438
Drug: Brimonidine bid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine bid (twice daily)
Study: 20852438
Drug: Brimonidine tid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine tid (three times daily)
Study: 10418209
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER (5-10 mg once daily, doubled if necessary)
Study: 10418209
Drug: Diltiazem SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem SR (90-180 mg once daily, doubled if necessary)
Study: 7592246
Drug: Diskus inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diskus inhaler (salmeterol 50 micrograms twice daily)
Study: 7592246
Drug: Diskhaler inhaler
Normalized name: zanamivir
DrugBank: Zanamivir (DB00558)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Diskhaler inhaler (salmeterol 50 micrograms twice daily)
Study: 2087855
Drug: Nisoldipine 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 0.3 mg
Study: 15528910
Drug: Sugar-free gum
Normalized name: Diabetic Multivitamin Sugar-Free Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-free gum containing 18.8 mg of CPP-ACP
Study: 9488234
Drug: Lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4 mg per day
Study: 8162007
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (1 g/d for 2 weeks followed by 1.5 g/d)
Study: 8162007
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (0.5 g/d for 1 month, 0.750 g/d during the second month, then 1 g/d)
Study: 3096633
Drug: 50 mcg
Normalized name: D3, 50 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg ethinyl estradiol and 1.0 mg ethynodiol diacetate (EED)
Study: 3096633
Drug: 50 mcg
Normalized name: D3, 50 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg ethinyl estradiol and 1.0 mg norethindrone acetate (ENA)
Study: 3096633
Drug: 50 mcg
Normalized name: D3, 50 mcg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mcg ethinyl estradiol and 0.5 mg d‐1 norgestrel (ENG)
Study: 21919543
Drug: Atorvastatin/metformin ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin/metformin ER 10mg/500mg FDC
Study: 21919543
Drug: Atorvastatin 10mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 10MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin 10mg (Lipitor®) and metformin 500mg (Glucophage® XR)
Study: 19883295
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (OTU) 80 mg twice daily
Study: 19883295
Drug: DHEA 50
Normalized name: Natrol Mood & Stress DHEA 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA 50 mg twice daily
Study: 17016711
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg)
Study: 12764904
Drug: TCM plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM plus western medicine
Study: 11734672
Drug: bezafibrate therapy
Normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bezafibrate therapy (400 mg/day for 6 weeks)
Study: 8060578
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 to 40 mg twice daily)
Study: 8060578
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 to 50 mg twice daily)
Study: 3051879
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg daily)
Study: 30455336
Drug: Insulin correction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin correction factor adjusted by 50%
Study: 30455336
Drug: Insulin correction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin correction factor adjusted by 100%
Study: 30455336
Drug: Insulin correction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin correction factor adjusted by 150%
Study: 30455336
Drug: Insulin correction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin correction factor adjusted by 0%
Study: 24917940
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg once daily
Study: 19911858
Drug: Prucalopride (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride (2 mg and 4 mg)
Study: 17064648
Drug: Allergoid SLIT
Normalized name: Coccidioides immitis spherule
DrugBank: Coccidioides immitis spherule (DB11294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergoid SLIT for grass pollens (active treatment)
Study: 15193479
Drug: Clomiphene citrate,
Normalized name: ClomiPHENE Citrate, 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomiphene citrate, high‐dose recombinant human FSH, and a delayed, multidose GnRH antagonist
Study: 10895837
Drug: Euglycemia (5.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (5.01 +/‐ 0.02 mmol/l) maintained for 225 +/‐ 3 min
Study: 10895837
Drug: Hypoglycemic condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic condition (plasma glucose at 2.65 +/‐ 0.02 mmol/l for 90 min)
Study: 8873690
Drug: Bumetanide (0.005
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (0.005 to 0.10 mg/kg, single intravenous dose)
Study: 24450390
Drug: T2D treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: T2D treatment
Study: 19446968
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine (placebo patch)
Study: 17046476
Drug: Continuous nebulized
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nebulized albuterol (15 mg) alone (A)
Study: 17046476
Drug: Continuous nebulized
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) (AI)
Study: 11095346
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b at a dose of 5 million units (MU) daily
Study: 11095346
Drug: Standard interferon
Normalized name: INTERFERON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard interferon at a dose of 3 MU three times a week (t.i.w.)
Study: 11095346
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b at a dose of 5 MU daily
Study: 6146499
Drug: Nadolol (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol (once daily)
Study: 6148868
Drug: Nadolol plus
Normalized name: Nadolol
DrugBank: Nadolol (DB01203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nadolol plus bendroflumethiazide (both once daily)
Study: 6359851
Drug: Hydralazine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine (25 to 100 mg twice daily)
Study: 31970931
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (topical prednisolone and cycloplegic drops with orbital floor injection of Triamcinolone acetonide)
Study: 25037665
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) for TMD
Study: 20522533
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (0.33 mg/kg per week)
Study: 15643481
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (SH) injection
Study: 16091920
Drug: Triamsinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamsinolone acetonide injection
Study: 30717815
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for antenatal depression
Study: 25034330
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Cistiquer
Study: 25034330
Drug: Intra-vesical administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-vesical administration of betametasone 8 mg plus gentamicin 80 mg
Study: 21505910
Drug: Low-dose XLGB
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose XLGB (3 g/day, n=61)
Study: 21505910
Drug: High-dose XLGB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose XLGB (6 g/day, n=58)
Study: 18625763
Drug: Raltegravir at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir at 400 mg twice daily for 4 days
Study: 18625763
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) at 300 mg once daily for 7 days
Study: 18625763
Drug: Raltegravir at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir at 400 mg twice daily plus TDF at 300 mg once daily for 4 days
Study: 11323536
Drug: TRT-100 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRT-100 (100 mg oral ketoprofen)
Study: 11323536
Drug: TRT-25 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRT-25 (25 mg oral ketoprofen)
Study: 7909525
Drug: Optimal intracellular
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal intracellular glutathione levels (20-30 nmol/mg protein)
Study: 7909525
Drug: Suboptimal intracellular
Normalized name: ACTIVIN RECEPTOR TYPE IIA (SYNTHETIC HUMAN EXTRACELLULAR DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (SYNTHETIC HUMAN HEAVY CHAIN FC FRAGMENT), DIMER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suboptimal intracellular glutathione levels (10-20 nmol/mg protein)
Study: 3209275
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg, verapamil 80 mg, diltiazem 60 mg three times a day (calcium antagonists)
Study: 3209275
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (Nifedipine, Verapamil, Diltiazem)
Study: 27984524
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (exercise + CBT)
Study: 21410107
Drug: AVI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVI with postoperative subconjunctival bevacizumab (SCB) injections (days 1 and 7)
Study: 11673930
Drug: Specific manipulative
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific manipulative therapy treatment
Study: 3339790
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of folate plus 500 micrograms of hydroxocobalamin
Study: 28914087
Drug: Myofascial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial therapy (12 sessions)
Study: 28914087
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical therapy program + Myofascial therapy
Study: 28914087
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (12 sessions)
Study: 16686645
Drug: Pregabalin (PGB)
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin (PGB) 600 mg/day
Study: 11741555
Drug: High-dose dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dobutamine stress echocardiography (up to 40 micro/kg/min)
Study: 11741555
Drug: High-dose dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dobutamine stress echocardiography
Study: 7587599
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) treatment, 3 x 10(6) U/day for 14 weeks
Study: 105697
Drug: Stannous fluoride
Normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stannous fluoride toothpaste used twice yearly for three years in supervised brush-ins
Study: 31013820
Drug: Sodium Citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Citrate (CIT) 600 mg·kg‐1
Study: 27660163
Drug: Bimonthly intravitreal
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimonthly intravitreal injections of aflibercept (IVA)
Study: 28402983
Drug: Pro re
Normalized name: Blistex Pro Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro re nata (PRN) treatment
Study: 26690036
Drug: Whole Body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Body Vibration Training (WBVT) for 6 weeks, 3 sessions per week, intensity varied from 7.2 g to 32.6 g
Study: 22083471
Drug: LAMB (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAMB (3 mg/kg once a day)
Study: 22083471
Drug: CAS (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAS (50 mg QD; day 1, 70 mg)
Study: 22083471
Drug: CAS-LAMB (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAS-LAMB (combination therapy)
Study: 19922894
Drug: DPSGC 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPSGC 25 mg under fasted condition
Study: 19922894
Drug: DPSGC 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPSGC 25 mg under fed condition
Study: 19922894
Drug: DPSGC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPSGC 50 mg under fasted condition
Study: 19922894
Drug: DPSGC 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPSGC 50 mg under fed condition
Study: 1257173
Drug: Inert pill
Normalized name: inert ingredients Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert pill (placebo)
Study: 1257173
Drug: Early drug
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early drug withdrawal
Study: 23594787
Drug: EOC (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: EOC (epirubicin 50 mg/m², oxaliplatin 130 mg/m², capecitabine 1250 mg/m²)
Study: 23594787
Drug: mEOC+P (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: mEOC+P (epirubicin 50 mg/m², oxaliplatin 100 mg/m², capecitabine 1000 mg/m², panitumumab 9 mg/kg)
Study: 12505859
Drug: 12-month maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12-month maintenance intervention with weekly telephone contacts and monthly supervised reinforcement sessions (n = 87)
Study: 9049568
Drug: Zinc (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (25 mg zinc as sulphate)
Study: 9049568
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A and Zinc (800 micrograms retinol palmitate and 25 mg zinc as sulphate)
Study: 9049568
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch containing capsules)
Study: 22686358
Drug: Web-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive-behavioral therapy (CBT) for 12 weeks
Study: 19860985
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Ca as calcium carbonate
Study: 17915969
Drug: Topiramate (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (target daily dose, 200 mg) plus cognitive-behavior therapy (CBT)
Study: 17915969
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus cognitive-behavior therapy (CBT)
Study: 15697072
Drug: Flutamide 250
Normalized name: flutamide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide 250 mg daily
Study: 12153602
Drug: CPA 2
Normalized name: Cyproterone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA 2 mg with 35 micro g ethinylestradiol
Study: 12153602
Drug: CPA 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPA 50 mg with 25 micro g ethinylestradiol
Study: 11446841
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg daily
Study: 10434235
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg (oral single dose)
Study: 7607582
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HELP treatment)
Study: 30151821
Drug: Dalteparin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin (200 IU/Kg daily for 30 days followed by 150 IU/kg daily thereafter)
Study: 26254585
Drug: Glycopyrrolate 10
Normalized name: glycopyrrolate 100% compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 10 μg/kg
Study: 26254585
Drug: Atropine 15
Normalized name: morphine sulfate/atropine 15/0.4 INJECTION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 15 μg/kg